AstraZeneca PLC (AZN)vsIndaptus Therapeutics Inc (INDP)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
INDP
Indaptus Therapeutics Inc
$2.80
-4.11%
HEALTHCARE · Cap: $7.69M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.4% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
INDP
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Intrinsic value data unavailable for INDP.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : INDP
The strongest argument for INDP centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : INDP
The primary concerns for INDP are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
INDP carries more volatility with a beta of 0.99 — expect wider price swings.
AZN is growing revenue faster at 4.1% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 21/100), backed by strong 17.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Indaptus Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Indaptus Therapeutics Inc. is a cutting-edge biotechnology firm focused on pioneering immunotherapies that aim to transform the landscape of cancer treatment. Utilizing a proprietary platform that enhances the immune system's capacity to identify and destroy tumor cells, the company is dedicated to increasing treatment efficacy and improving patient outcomes. With a robust portfolio of clinical candidates addressing critical unmet medical needs within oncology, Indaptus is strategically positioned for growth in an increasingly competitive market. Its dedication to scientific innovation and partnerships with leading research institutions highlights its potential as a transformative force in the biopharmaceutical sector.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?